Irm LLC

Life Technologies Corporation

Elanco Tiergesundheit Ag

Other

Novartis Ag

Genetics Institute, Inc.

F. Hoffmann-la Roche Ag

Bioprocess Pty Ltd.

Marc Nasoff

Quinn L Deveraux

Joseph M Fernandez

James P Hoeffler

Brendan P Eckelman

Robert Charles Downs

James Kevin Mainquist

Genevieve Inchauspe

Sarah Rue

Andrew J Meyer

Scott Allan Lesley

Liqun Dong

Deborah A Knee

Pedro Aza-Blanc

Daniel Terence McMullan

Klaus Wagner

Suzanne Zebedee

Alfred M Prince

Paul F Schendel

Michael F Nunn

Torsten B Helting

Garret M Hampton

Steve B Cohen

Garrett M Hampton

Alfred S Prince

Patricia Raney

This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.

Monoclonal antibodies and methods of use

Monoclonal canine CD20 antibodies and methods of use

Methods of using microarrays to simplify analysis and characterization of genes and their function are provided. Such methods can be used to identify and characterize antibodies having binding affinity for a specific target antigen. A method of determining gene expression at the protein level by contacting an array of characterized or uncharacterized antibodies on a solid surface with one or more proteins and identifying the antibodies to which said protein(s) binds also is provided. This method can be used to compare the protein expression in two different populations of cells, such as normal cells and cancer cells or resting cells and stimulated cells. In addition, a method of determining gene expression at the protein level by contacting a microarray of nucleic acid samples derived from a variety of different sources with one or more nucleic acid probes then identifying the sample or samples to which the probe binds is provided.

Microarrays and uses therefor

Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.

Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody

Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.

Methods and compositions for treating allergic diseases

The present invention provides antibodies or antigen-binding molecules that specifically recognize and antagonize human PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.

Antagonists of protease activated receptor-1 (PAR1)

The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors are transformed into host cells and used in a method to express large quantities of these antigens. The invention also provides compositions containing certain of the isolated antigens, diagnostic systems containing these antigens and methods of assaying body fluids to detect the presence of antibodies against the antigens of the invention.

Method for detecting NANBV associated seroconversion

The invention disclosed herein comprises methods of using microarrays to simplify analysis and characterization of genes and their function. In one aspect of the invention the methods are used to identify and characterize antibodies having binding affinity for a specific target antigen. The invention further comprises a method of determining gene expression at the protein level comprising contacting an array of characterized or uncharacterized antibodies on a solid surface with one or more proteins and identifying the antibodies to which said protein(s) binds. This method can be additionally used to compare the protein expression in two different populations of cells, such as normal cells and cancer cells or resting cells and stimulated cells. A further aspect of the invention comprises a method of determining gene expression at the protein level comprising contacting a microarray of nucleic acid samples derived from a variety of different sources with one or more nucleic acid probes then identifying the sample or samples to which the probe binds.

Microarray and uses therefor

Anti-DR4 or Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.

Methods and compositions for inducing apoptosis in cancer cells

A fermentation apparatus is constructed to produce a known and repeatable amount of untainted fermentation product using multiple fermentation vessels. To facilitate further processing compatible with other product processing steps, the fermentation apparatus has an array of sample vessels arranged in a container frame. The container frame is configured to hold the sample vessels during fermentation and to transport the vessel array to or from another processing station. Corresponding to the number of sample vessels in the sample vessel array, a cannula array is configured such that each cannula may be placed inside a sample vessel. The cannula array is attached to a gas distributor that delivers oxygen and/or one or more other gases from a gas source through the cannula into the sample vessel. Because the fermentation volume for each individual sample vessel is smaller than a bulk fermentation apparatus, the fermentation product yields are predictable and cell growth rates can be effectively optimized.

Multi-sample fermentor and method of using same

The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors are transformed into host cells and used in a method to express large quantities of these antigens. The invention also provides compositions containing certain of the isolated antigens., diagnostic systems containing these antigens and methods of assaying body fluids to detect the presence of antibodies against the antigens of the invention.

Methods and systems for producing recombinant viral antigens

A fermentation apparatus is constructed to produce a known and repeatable amount of unpoisoned fermentation product using multiple fermentation vessels. To facilitate further processing compatible with other product processing steps, the fermentation apparatus has an array of sample vessels arranged in a container frame. The container frame is configured to hold the sample vessels during fermentation and to transport the vessel array to or from another processing station. Corresponding to the number of sample vessels in the sample vessel array, a cannula array is configured such that each cannula may be placed inside a sample vessel. The cannula array is attached to a gas distributor that delivers oxygen and/or one or more other gases from a gas source through the cannula into the sample vessel. Because the fermentation volume for each individual sample vessel is smaller than a bulk fermentation apparatus, the fermentation product yields are more predictable and cell growth rates may be more effectively optimized.

An improved bacterial host cell useful for the inducible production and secretion in high yields of a heterologous protein is provided which contains a gene encoding the heterologous protein operatively linked to a secretory leader-encoding sequence and to an expression control sequence which contains a promoter region; and a second DNA sequence encoding a repressor capable of binding to said promoter region. The cell contains at least a mutation in the repressor binding region of the promoter or a mutation in the promoter binding region of the repressor-encoding sequence; or mutations in both regions. These mutation(s) lower the frequency of transcriptional induction by the promoter from the observed with the wild-type promoter and/or repressor-encoding sequence, resulting in higher yields of secreted heterologous protein.

Growing community of inventors

San Diego, CA, United States of America

Marc Nasoff